Cyclotraxin-B, the first highly potent and selective TrkB inhibitor, has anxiolytic properties in mice.
In the last decades, few mechanistically novel therapeutic agents have been developed to treat mental and neurodegenerative disorders. Numerous studies suggest that targeting BDNF and its TrkB receptor could be a promising therapeutic strategy for the treatment of brain disorders. However, the devel...
Saved in:
| Main Authors: | Maxime Cazorla, Anne Jouvenceau, Christiane Rose, Jean-Philippe Guilloux, Catherine Pilon, Alex Dranovsky, Joël Prémont |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2010-03-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0009777&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
BDNF/TrkB signaling in stable coronary artery disease
by: O. V. Atamas, et al.
Published: (2023-12-01) -
Downregulated GABA and BDNF-TrkB Pathway in Chronic Cyclothiazide Seizure Model
by: Shuzhen Kong, et al.
Published: (2014-01-01) -
Exercise-induced neurogenesis through BDNF-TrkB pathway: implications for neurodegenerative disorders
by: Lee Jun Jie, et al.
Published: (2025-02-01) -
Activation of BDNF–TrkB Signaling in Specific Structures of the Sheep Brain by Kynurenic Acid
by: Katarzyna Roszkowicz-Ostrowska, et al.
Published: (2024-11-01) -
A Small-Molecule TrkB/TrkC Ligand Promotes Neurogenesis and Behavioral Recovery Following Traumatic Brain Injury
by: Jian Shi, et al.
Published: (2025-01-01)